Side-by-side research comparison of Humanin and MOTS-c across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 16 head-to-head studies plus 45 on Humanin and 121 on MOTS-c.
| Humanin | MOTS-c | |
|---|---|---|
| Drug class | n/a | mitochondrial peptide |
| Studies in corpus | 45 | 121 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | in vitro · 4 preclinical animal · 8 other · 13 cohort · 3 review · 6 rct · 1 meta analysis · 1 | other · 36 review · 9 cohort · 6 preclinical animal · 37 in vitro · 8 meta analysis · 1 |
| Studies with explicit sample size | 1 | 1 |
| Head-to-head studies in corpus | 16 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Humanin and MOTS-c batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 27 Humanin batches across 15 manufacturers, 95.94% avg purity.
We tested 3692 MOTS-c batches across 1278 manufacturers, 99.46% avg purity.
We hold deeper lab coverage on MOTS-c (3692 batches tested). MOTS-c edges ahead on average measured purity (95.94% vs 99.46%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Humanin and MOTS-c — the gold-standard direct comparison evidence.
This comprehensive systematic review and meta-analysis solidifies the critical role of Mitochondrial Derived Peptides (MDPs) in metabolic regulation and disease pathogenesis. The consistent and robust correlations observed across numerous studies highlight …
This review establishes a crucial link between mitochondrial-derived microproteins and the pathogenesis of both cancer and neurodegenerative diseases, offering a novel perspective on disease etiology. By identifying common mechanistic pathways, it opens new…
This review highlights a significant untapped area of research with profound implications for understanding and treating lung diseases. Given the established roles of MDPs in other complex diseases, their investigation in pulmonary contexts could uncover no…
The findings underscore the significant therapeutic potential of mitochondrial-derived peptides as a novel class of agents for preventing and treating vascular aging and associated cardiovascular diseases. By targeting fundamental cellular processes like mi…
This review significantly advances our understanding of mitochondria-derived peptides (MDPs) as critical regulators of hepatic metabolism and potential therapeutic agents. The identification of MDPs like MOTS-c and Humanin as key players in combating liver …
This review underscores the immense therapeutic potential of mitochondria-derived peptides as a novel class of agents for treating cardiovascular diseases. By directly targeting mitochondrial dysfunction, MDPs offer a unique approach to not only manage symp…
This research is significant as it identifies Humanin and MOTS-c as potential protective agents against chemotherapy-induced reproductive damage. Given the devastating impact of male infertility on cancer survivors, finding effective interventions is crucia…
This research strongly positions mitochondrial-derived peptides as a novel and potent class of therapeutic agents for the management of Type 2 Diabetes. Their ability to simultaneously improve insulin sensitivity, reduce hepatic glucose production, and rest…
This research provides compelling evidence that MOTS-c and humanin could represent novel therapeutic agents for preventing or treating muscle atrophy, particularly in contexts involving corticosteroid use or other catabolic states. The ability of these mito…
Looking for vendor-level purity, endotoxin, and HPLC data on Humanin or MOTS-c? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.